CTNT

Executive Summary

CTNT is a privately-owned contract research organization (CRO) based in Tel Aviv, Israel, founded in 2020. The company provides comprehensive clinical development services, including trial management, regulatory affairs, quality assurance, pre-clinical consulting, medical writing, and decentralized clinical trial (DCT) solutions. By leveraging digital platforms for remote patient monitoring and data capture, CTNT supports pharmaceutical, biotechnology, and medical-device sponsors across all phases of clinical research. The company has executed over 70 studies, emphasizing high-quality, compliant execution, particularly in niche therapeutic areas. As a young CRO with a specialized focus and DCT capabilities, CTNT is well-positioned to capitalize on the growing demand for decentralized trials and the increasing outsourcing of clinical services by sponsors. However, the company faces competitive pressures from larger, established CROs and must navigate regulatory complexities across different geographies. Its private status and lack of disclosed funding details suggest a need for future capital to scale operations and expand its client base. Overall, CTNT presents a promising but early-stage opportunity in the clinical research market.

Upcoming Catalysts (preview)

• Q3 2026Announcement of a Strategic Partnership with a Large Pharmaceutical Company40% success
• Q4 2026Completion of Series A Funding Round to Expand Operations and Technology35% success
• Q1 2027Entry into a New Geographic Market (e.g., U.S. or EU) via Regulatory Approval30% success